Chimeric Therapeutics (ASX:CHM)
We spoke to Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics (ASX: CHM), about the three exciting programmes in CAR-T and NK cells, and the favourable clinical data that has been gathered in a range of cancers.
Chimeric’s share price is down a long way since the 2021 IPO, but the prospects for good licensing deals going forward is strong.
Check our ASX buy/sell tips
